瞬时受体潜在阳离子通道,亚家族V,成员1(TRPV1)是非选择性阳离子通道,可被多种有害刺激物(包括辣椒素,酸和热)激活。正在研究选择性拮抗剂对TRPV1激活的阻断作用,以试图鉴定用于疼痛治疗的新型药物。在临床前开发过程中,1,8-萘啶2表现出高水平的不可逆共价结合。用吡啶并[2,3- b ]吡嗪取代1,8-萘啶核心导致发现化合物26,该化合物显示出显着较低的反应性代谢物形成潜能。化合物26被表征为具有中等脑渗透性的口服生物利用型TRPV1拮抗剂。体内给药后,有26种药物显着减轻了角叉菜胶引起的热痛觉过敏(CITH),并剂量依赖性地降低了完全弗氏佐剂(CFA)引起的慢性炎性疼痛。
Substituted biaryl quinolin-4-ylamine analogues of Formula I are provided.
Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.